Rockefeller University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rockefeller University sits in the top decile of US sponsors by registered trial count (#222 of 15,742 sponsors by registered trial count).
Rockefeller University: 117 sponsored US clinical trials, 5 recruiting.
Rockefeller University sponsors 117 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 92 completed. 7 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 5 trials.
Top-decile sponsor footprint
Rockefeller University ranks in the top decile of sponsors by registered trial count (#222 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
92 of 109 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
117 total, page 1 of 3
Thermogenic Silencer Regulatory Factors in Humans
NCT06424132
HepB mAb19 in Individuals With Chronic Hepatitis B Infection
NCT05856890
Predictors of Aspirin Failure in Preeclampsia Prevention
NCT05709483
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
NCT05272735
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
NCT00230165
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
NCT05245292
BATokines as Biomarkers of Brown Fat in Humans
NCT05050240
Discovering the Antecedents of Rheumatoid Arthritis Flare
NCT02051114
The Impact of Time Restricted Eating on Type 2 Diabetes
NCT06887543
Myokine Identification Following Acute Exercise
NCT06223035
Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress
NCT06146218
Effect of Antibiotics on Enteric Neurons and Glia
NCT05834036
Racism-based and Biomarkers of Stress
NCT05574933
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
NCT04979520
Time-Restricted Feeding
NCT04884659
RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
NCT04700163
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
NCT04250636
When the Kidney Reacts to Nutritional Changes
NCT04142138
A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
NCT04059588
DASH Diet Intervention at Senior Centers
NCT03993808
Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
NCT03960268
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
NCT03554408
3BNC117 and 10-1074 in ART-treated Individuals
NCT03526848
Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
NCT03339245
3BNC117-LS First-in-Human Phase 1 Study
NCT03254277
Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis
NCT03083730
Romidepsin Plus 3BNC117 Phase 2a Study
NCT02850016
Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
NCT02347345
Yellow Fever Immune Response at Single Cell Resolution
NCT03458780
3BNC117 and 10-1074 in HIV Uninfected Adults
NCT02824536
3BNC117 and 10-1074 in HIV-infected Individuals
NCT02825797
Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury
NCT02732288
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
NCT02653495
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
NCT02590068
A Study of the Safety and Antiretroviral Activity of 3BNC117
NCT02588586
Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)
NCT02470273
Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption
NCT02520258
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
NCT02511990
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
NCT02429583
Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
NCT02725684
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
NCT02446847
Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
NCT02055365
A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR
NCT01889719
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
NCT02018510
Comparative Analysis of Small and Large Plaque Psoriasis
NCT01920906
Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
NCT01941537
Pilot Study for Noninvasive Spectroscopic Detection of Adipose Tissue Inflammation in Obesity
NCT01900366
Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
NCT01901679
A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin
NCT02338076
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
NCT01806662
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the Rockefeller University pipeline
5 recruiting of 117 indexed (4% open); 92 completed (79%).
Phase mix: 7 late (III/IV) vs 43 early (I/II) (early-phase heavy).
Top condition: Obesity (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rockefeller University: open-pipeline peers nationwide
Peers matched on 117 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Rockefeller University sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 117 trials (± recruiting share)
- San Diego State University · 118 trials · 27% recruiting
- Children's Hospital Los Angeles · 119 trials · 29% recruiting
- Jaeb Center for Health Research · 119 trials · 14% recruiting
- Medtronic - MITG · 119 trials · 4% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Craig L Slingluff, Jr · 4% recruiting · 23 trials
- Esperion Therapeutics · 4% recruiting · 23 trials
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
- National Institute on Drug Abuse (NIDA) · 4% recruiting · 335 trials
Related
What to do with this Rockefeller University page
117 registered trials is a research-attention snapshot, not an endorsement of Rockefeller University or any single study.
- 5 of Rockefeller University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Rockefeller University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rockefeller University pipeline card: 117 registered trials from official public datasets.Report a data error.